Drugs / BI 187004
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT02305901 | Dec 2014 → Mar 2015 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02254148 | Oct → Dec 2014 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02161432 | Jun → Sep 2014 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02109679 | May → Jul 2014 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01874483 | Jun → Dec 2013 | type 2 diabetes mellitus | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01587417 | Apr → Oct 2012 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02150824 | Jul 2014 → Jul 2015 | type 2 diabetes mellitus | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 187004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02150824 ↗ |
| Action | Inhibit | “BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1” PMID 34391480 ↗ Aug 20211“11-beta-hydroxysteroid dehydrogenase 1 inhibitor” CHEMBL3669417 ↗ |
| Modality | Small molecule | — CHEMBL3669417 ↗ |
| Route | Oral | “single oral doses of BI 187004” PMID 34391480 ↗ Aug 2021 |
| Target | HSD11B1 | “11-beta-hydroxysteroid dehydrogenase 1 inhibitor” CHEMBL3669417 ↗ |